By Michael Balsamo and Ann D'Innocenzio

The Justice Department is suing Walmart, alleging the company unlawfully dispensed controlled substances through its pharmacies, helping to fuel the opioid crisis in America.

The civil complaint being filed Tuesday points to the role Walmart’s pharmacies may have played in the crisis by filling opioid prescriptions and by unlawfully distributing controlled substances to the pharmacies during the height of the opioid crisis. Walmart operates more than 5,000 pharmacies in its stores around the country.

The Justice Department alleges Walmart violated federal law by selling thousands of prescriptions for controlled substances that its pharmacists “knew were invalid,” said Jeffrey Clark, the acting assistant attorney general in charge of the Justice Department’s civil division.

Federal law required Walmart to spot suspicious orders for controlled substances and report those to the Drug Enforcement Administration, but prosecutors charge the company didn’t do that. Walmart couldn’t immediately be reached for comment.

“Walmart knew that its distribution centers were using an inadequate system for detecting and reporting suspicious orders,” said Jason Dunn, the U.S. attorney in Colorado. “As a result of this inadequate system, for years Walmart reported virtually no suspicious orders at all. In other words, Walmart’s pharmacies ordered opioids in a way that went essentially unmonitored and unregulated.”

The suit alleges that Walmart made it difficult for its pharmacists to follow the rules, putting “enormous pressure" on them to fill a high volume of prescriptions as fast as possible, while at the same time denying them the authority to categorically refuse to fill prescriptions issued by prescribers the pharmacists knew were continually issuing invalid prescriptions.

AP reported the news of the lawsuit ahead of the Justice Department's public announcement, citing a person who could not discuss the matter publicly before the announced move. The person spoke to the AP on condition of anonymity.

The Justice Department’s lawsuit comes nearly two months after Walmart filed its own preemptive suit against the Justice Department, Attorney General William Barr, and the Drug Enforcement Administration.

In its lawsuit, Walmart said the Justice Department’s investigation — launched in 2016 — had identified hundreds of doctors who wrote problematic prescriptions that Walmart’s pharmacists should not have filled. But the lawsuit charged that nearly 70% of the doctors still have active registrations with the DEA.

Walmart’s lawsuit alleged the government was blaming it for the lack of regulatory and enforcement policies to stem the crisis. The company is asking a federal judge to declare the suit has no basis to seek civil damages. That suit remains ongoing.

The initial investigation was the subject of a ProPublica story published in March. ProPublica reported that Joe Brown, then U.S. attorney for the Eastern District of Texas office, spent years pursuing a criminal case against Walmart for its opioid prescription practices, only to have it stymied after the retail giant’s lawyers appealed to senior officials in the Justice Department.

Two months later, Brown resigned. He didn’t give a reason for his departure except to say he would be “pursuing opportunities in the private and public sectors." Brown went into private practice in the Dallas area.

Updated on December 22, 2020, at 3:44 p.m. ET with additional details.

Share:
More In Business
Walmart, Kroger Raise At-Home COVID-19 Test Prices
Americans looking to purchase at-home COVID-19 tests will now have to shell out a bit more money after an agreement expired between the White House and companies to sell the tests at cost. The price of Abbot's BinaxNow test kit from October to December was $14 apiece; on Tuesday, Walmart's website listed the test for $19.88, and Kroger listed the tests for $23.99. Carbon Health Regional Clinical Director Dr. Bayo Curry-Winchell joined Cheddar News' Closing Bell to discuss the impact higher prices will have as the nation experiences another surge in cases.
Entertainment Stocks to Watch in 2022
The streaming wars picked up in 2021, but what can we expect to see in 2022 as the global economy re-opens? Wall Street is likely to spend much of the new year debating where to place bets in the new year, and specifically which entertainment stocks to focus on. Tuna Amobi, media and entertainment analyst at CFRA research, joins Cheddar News to share his top picks.
The Self-Driving Vehicle Industry In 2022
2022 is set to be a big year for autonomous technology. After many new partnerships, acquisitions, and developments in 2021, all eyes will be on the self-driving sector to see what progress, or lack there-of, will be made this year. Soroush Salehian, CEO and co-founder of Aeva, gives a look at what's ahead for the industry.
CES 2022: Top Tech Trends To Watch
The largest tech convention in the world kicks off this week. CES, organized by the Consumer Technology Association, will run from Wednesday Jan. 5 through Friday Jan. 7, featuring more than 2,000 exhibitors showing off their latest tech products in Las Vegas. Ian Sherr, editor at large at CNET, gives a first look at some of the biggest trends expected this year.
Verizon, AT&T Battle Out 5G Rollout With Airline Industry
Verizon and AT&T have agreed to delay the launch of their 5G networks for two weeks following pressure from the Federal Aviation Administration, airline companies and even Transportation Secretary Pete Buttigieg. The aviation industry is concerned the 5G rollout could bring technical challenges or safety concerns on top of the current disruptions they're already dealing with from COVID and severe weather. Hugh Odom, founder and president of Vertical Consultants and former AT&T attorney, discusses how the Biden administration was able to come to this agreement with the wireless carriers.
Load More